Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
ProShares UltraShort Bloomberg Crude Oil (SCO) Climbs +33% as Oil Prices Collapse

ProShares UltraShort Bloomberg Crude Oil (SCO) Climbs +33% as Oil Prices Collapse

Key Takeaways

  • SCO surged approximately 33% over the past 30 days as crude oil prices collapsed, driven by the reopening of the Strait of Hormuz and a historic supply glut.
  • The fund's -2x leveraged inverse structure amplifies daily moves in the opposite direction of the Bloomberg Commodity Balanced WTI Crude Oil Index, magnifying gains when oil prices fall.
  • Brent crude tumbled from its April peak near $138 per barrel to roughly $71 in early July, while WTI fell from approximately $109 to around $68, creating a powerful tailwind for inverse oil positions.
  • The US-Iran memorandum of understanding signed on June 17 accelerated the unwinding of the geopolitical risk premium, triggering the steepest monthly decline in oil since March 2020.
  • OPEC+ production increases, record Russian shipments, and the release of more than 60 million barrels of previously trapped crude have swung the market from deficit to surplus.

ProShares UltraShort Bloomberg Crude Oil (SCO) Overview and Portfolio Exposure

SCO is a leveraged inverse exchange-traded fund (ETF) that seeks to deliver -2x the daily performance of the Bloomberg Commodity Balanced WTI Crude Oil Index. The fund is designed for short-term tactical positioning rather than buy-and-hold investing, using derivatives such as futures contracts and swaps to achieve its inverse exposure. Because it resets daily, compounding effects can cause returns over periods longer than one day to deviate from a simple -2x multiple of the index's return.

The ETF's portfolio is concentrated in crude oil futures and related derivative instruments, making it a pure play on the direction of West Texas Intermediate crude oil prices. With an expense ratio of approximately 0.95%, SCO is structured for sophisticated investors seeking to hedge commodity exposure or express a bearish view on oil. The fund carries significant volatility and is sensitive to daily price swings in the underlying commodity, which have been exceptionally large during the recent geopolitical turmoil in the Middle East.

SCO Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending in mid-July 2026, SCO climbed from approximately $25.23 to around $33.62, representing a gain of roughly 33%. The advance was not linear; the ETF experienced sharp rallies interspersed with brief pullbacks as oil prices whipsawed on shifting headlines around the Strait of Hormuz and US-Iran negotiations. The most pronounced leg higher occurred in the second half of June, coinciding with the signing of the US-Iran memorandum of understanding and the rapid recovery of crude flows through the strategic waterway.

Over the broader quarter, SCO has delivered substantial gains as crude oil prices collapsed from their wartime peaks. In early April, Brent crude traded near $138 per barrel and WTI approached $109, levels that likely placed SCO near multi-month lows. As the geopolitical risk premium evaporated and supply flooded back into the market, SCO rallied powerfully. From early May through mid-July, the ETF gained approximately 25%, with the bulk of those gains concentrated in June as the oil market's structure flipped from backwardation to contango, signaling a shift from scarcity to surplus.

What Drove SCO Price in the Last 30 Days

The primary catalyst for SCO's 33% surge was the dramatic collapse in crude oil prices triggered by the reopening of the Strait of Hormuz. On June 17, the United States and Iran signed a 14-point memorandum of understanding that ended military conflict and established a framework for reopening the strait, which handles roughly 20% of global oil supply. The agreement unleashed a flood of returning supply: UAE exports recovered to over 3.9 million barrels per day, Iranian oil exports jumped above 40 million barrels following the lifting of the American naval blockade, and total crude flows through the strait exceeded 10 million barrels per day.

Compounding the supply recovery, OPEC+ agreed to raise production targets by an additional 188,000 barrels per day from August, following similar hikes announced for June and July. Record Russian shipments added further pressure. On the demand side, Chinese crude imports remained depressed, running roughly 30% below year-earlier levels in May and falling further in June. The International Energy Agency (IEA) revised its 2026 demand forecast to a contraction of approximately 1 million barrels per day. The combination of surging supply and weak demand pushed Brent below $71 and WTI below $68, levels not seen since before the conflict began in late February. For SCO, which moves inversely to oil prices with 2x leverage, this environment proved exceptionally favorable.

What Drove SCO Performance Over the Last Quarter

SCO's quarterly performance reflects the broader unwinding of the geopolitical risk premium that had been embedded in crude oil prices since the Iran conflict erupted on February 28. During the second quarter, Brent crude recorded a decline of roughly 30%, its largest quarterly drop since 2020, while WTI fell more than 20%. The market transitioned from a deficit of approximately 2 million barrels per day during the height of the conflict to a projected surplus of about 1 million barrels per day by the fourth quarter of 2026.

Several structural forces reinforced the downtrend in oil. US shale production held near record levels of 13.6 million barrels per day. The US Strategic Petroleum Reserve continued releasing barrels even as the emergency faded. Global oil inventories held on water climbed by 117 million barrels in June alone. Meanwhile, JPMorgan and Macquarie both slashed their oil price forecasts, with Macquarie cutting its 2026 Brent average estimate from $89 to $77 per barrel. The persistent decline in crude prices, punctuated by brief spikes on renewed military clashes, provided a sustained tailwind for SCO throughout the quarter.

Using Tickeron’s AI Screener for ETF Research

Identifying ETFs with strong momentum like SCO often benefits from systematic screening tools. I also checked this using Tickeron’s AI Screener to compare the fund against other inverse commodity vehicles and momentum candidates in the sector. The platform allows filtering by technical indicators, volatility metrics, and performance patterns, which can help surface ideas more efficiently when markets are moving quickly. In my view, incorporating such a tool into the research process provides an additional layer of perspective alongside traditional analysis, particularly for leveraged products that require close monitoring of daily resets and compounding effects.

SCO ETF Outlook: What Investors Should Watch Next

The trajectory of SCO in the coming months will depend heavily on whether the current oil supply glut persists or tightens. The most critical variable is the durability of the US-Iran ceasefire and the pace of further normalization through the Strait of Hormuz. While crude flows have recovered significantly, they remain roughly 40% below pre-war levels, and renewed military exchanges in early July demonstrated the fragility of the situation. Any breakdown in negotiations could send oil prices sharply higher, creating headwinds for SCO.

Chinese demand represents another pivotal factor. Chinese crude imports have been running well below normal levels, and a meaningful return of Chinese buying could absorb some of the excess supply, potentially stabilizing or lifting oil prices. Conversely, if Chinese demand remains subdued and OPEC+ continues adding barrels, the surplus could deepen, providing further support for inverse oil positions. Investors should also monitor US inventory data, which has shown twelve consecutive weeks of drawdowns, leaving domestic stockpiles at multi-year lows. The need to rebuild inventories could provide a floor under oil prices. Additionally, the Federal Reserve's monetary policy path and its impact on the US dollar will influence dollar-denominated commodity prices. As a leveraged inverse product, SCO is best suited for short-term tactical use, and investors should remain attentive to the compounding effects and volatility decay inherent in daily-reset leveraged funds.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCO

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


SCO's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for SCO moved out of oversold territory on July 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on SCO as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SCO just turned positive on August 03, 2026. Looking at past instances where SCO's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCO advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

SCO moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SCO crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SCO broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SCO entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Bloomberg Commodity Balanced WTI Crude Oil IndexSM. The fund seeks to meet its investment objective by investing, under normal market conditions, in any one of, or combinations of, Financial Instruments (including swap agreements, futures contracts, forward contracts, and option contracts) based on WTI sweet, light crude oil. It will not invest directly in oil.
View a ticker or compare two or three
SCO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Inverse Commodities
Address
ProShares Trust II7501 WISCONSIN AVEBethesda
Phone
240-497-6400
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.